Dr. Rengarajan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-726-3872Fax+1 617-726-5905
Education & Training
- Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2018 - 2022
- Brigham and Women's HospitalResidency, Internal Medicine, 2016 - 2018
- Stanford University School of MedicineClass of 2016
Certifications & Licensure
- MA State Medical License 2016 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- Concerns in Interpretation of Results In the Identification of Immune Checkpoint Inhibitor-Induced Diabetes-Reply.Karina N Ruiz-Esteves, Aaron J Deutsch, Michelle Rengarajan
JAMA Oncology. 2025-01-30 - 3 citationsIdentification of Immune Checkpoint Inhibitor-Induced Diabetes.Karina N Ruiz-Esteves, Kaitlyn R Shank, Aaron J Deutsch, Alekhya Gunturi, Natalia Chamorro-Pareja
JAMA Oncology. 2024-10-01 - 1 citationsCase 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.Jonathan R Wing, Allison Kimball, Michelle Rengarajan
The New England Journal of Medicine. 2022-02-24
Press Mentions
- Identification of Immune Checkpoint Inhibitor–Induced DiabetesAugust 29th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: